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Summary
Objective:  Previous  research  found  that  variants  of  the  glucocorticoid  receptor  (GR)  (9,
ER22/23EK,  BclI, TthIIIl,  NR3C1-1  and  N363S)  and  mineralocorticoid  receptor  (MR)  gene  poly-
morphism  (−2  C/G  and  I180V)  are  associated  with  both  glucocorticoid  (GC)  sensitivity  and  major
depressive  disorder  (MDD).  There  are  no  data  which  investigated  prospectively  whether  these
variants  are  associated  with  recurrence  of  MDD.
Methods:  Data  were  derived  from  the  Netherlands  Study  of  Depression  and  Anxiety  (NESDA)
which used  the  Composite  International  Diagnostic  Interview  (CIDI)  to  determine  MDD.  Poly-
morphisms  in  the  GR  and  MR  gene  were  determined  and  haplotypes  were  characterized.  We
analyzed in  retrospect  whether  recurrent  MDD  (n  =  951)  in  comparison  with  ﬁrst  onset  MDD
(n =  919)  was  associated  with  polymorphisms  in  the  GR  and  MR  gene.  Furthermore,  we  ana-
lyzed prospectively  for  4  years  the  time  to  recurrence  among  683  subjects  with  a  remitted
MDD diagnosis.  Time  to  recurrence  of  MDD  was  assessed  using  the  CIDI  and  a  life  chart  inter-
view. Additionally,  we  analyzed  interactions  of  the  investigated  polymorphisms  with  childhood
trauma and  recent  negative  life  events.
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Results:  GR  and  MR  gene  polymorphisms  and  derived  haplotypes  were  not  associated  with  recur-
rence of  depression  in  both  retrospective  and  prospective  analyses.  In  addition,  no  consistent
interactions  between  GR  and  MR  polymorphisms  and  childhood  trauma  or  life  events  were  found.
Conclusion:  This  study  did  not  ﬁnd  consistent  associations  between  GR  and  MR  gene  polymor-
phisms, interactions  between  GR  and  MR  haplotypes  and  stressful  conditions  and  recurrence  of
MDD.
© 2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Major  depressive  disorder  (MDD)  is  one  of  the  disor-
ders  with  the  highest  morbidity  worldwide  (World  Health
Organisation,  2008)  and  long  term  strategies  aimed  at  reduc-
ing  recurrence  could  be  an  effective  way  to  reduce  the
population  burden  of  MDD  (Vos  et  al.,  2004).  However,
knowledge  of  the  predictors  of  recurrence  is  still  sparse.
MDD  is  a  complex  disorder  that  does  not  result  from  either
genetic  or  environmental  inﬂuences  alone  but  rather  from
both.
A  possible  link  between  environmental  inﬂuences,  e.g.
stressful  conditions,  genetic  risk  factors  and  the  risk  for
a  recurrence  of  MDD  could  be  an  altered  function  of  the
hypothalamic—pituitary—adrenal  (HPA)  axis.  In  reaction  to
stressful  conditions,  glucocorticoids  coordinate  metabolic,
endocrine,  immune  and  nervous  system  responses.  Recurr-
ences  of  MDD  are  associated  with  childhood  trauma
(Hardeveld  et  al.,  2013),  recent  life  events  (Monroe  et  al.,
2014)  and  HPA-axis  alterations  (Ribeiro  et  al.,  1993;  Zobel
et  al.,  1999,  2001;  Harris  et  al.,  2000;  Hatzinger  et  al.,  2002;
Bhagwagar  et  al.,  2003;  Appelhof  et  al.,  2006;  Aubry  et  al.,
2007;  Bhagwagar  and  Cowen,  2008;  Pintor  et  al.,  2009;
Rao  et  al.,  2010;  Bockting  et  al.,  2012;  Vrshek-Schallhorn
et  al.,  2013).  It  has  been  postulated  that  childhood  trauma
can  induce  persistent  changes  in  the  response  of  the  HPA
axis,  which  can  become  apparent  when  persons  are  exposed
to  psychosocial  stressors  in  adulthood  (Von  Werne  Baes
et  al.,  2012;  Juruena,  2014).  A  recent  study  (Hardeveld
et  al.,  2014)  published  in  this  journal  concluded  that  the
cortisol  awakening  response  was  associated  with  time  to
recurrence  of  MDD  and  it  was  postulated  that  an  increased
cortisol  awakening  response  could  also  be  a  genetic  vulner-
ability  trait.  The  effects  of  glucocorticoids  are  mediated
by  the  glucocorticoid  receptor  (GR)  and  mineralocorticoid
receptor  (MR)  and  altered  sensitivity  to  glucocorticoids  of
both  receptors  could  lead  to  reduced  negative  feedback  of
cortisol,  an  increased  production  of  corticotrophin  releas-
ing  factor  and  consequently  hypercortisolism  which  has
been  associated  with  the  pathophysiology  of  MDD  (gluco-
corticoid  cascade  hypothesis)  (Nemeroff,  1996;  Holsboer,
2000;  Pariante,  2009).  Sensitivity  to  glucocorticoids  varies
between  individuals  (Stevens  et  al.,  2004)  and  various  com-
mon  single  nucleotide  polymorphisms  (SNPs)  are  associated
with  glucocorticoid  sensitivity  (Spijker  and  van  Rossum,
2012).  For  the  MR  gene  these  are:  −2  G/C  and  I180V  (De  Rijk
et  al.,  2006;  Van  Leeuwen  et  al.,  2011)  and  for  the  GR  gene
these  are:  22/23  EK,  9,  N363S,  TthIIIl, NR3C1-1,  and  BclI
(Huizenga  et  al.,  1998;  Van  Rossum  et  al.,  2002,  2003;  Wüst
et  al.,  2004;  Spijker  and  van  Rossum,  2012).  Studies  also
found  that  these  polymorphisms  were  associated  with  onset
and  presence  of  major  depression  (Van  Rossum  et  al.,  2006;
Van  West  et  al.,  2006;  Kuningas  et  al.,  2007;  Zobel  et  al.,
2008;  Krishnamurthy  et  al.,  2008;  Bet  et  al.,  2009;  Otte
et  al.,  2009;  Klok  et  al.,  2011;  Spijker  and  van  Rossum,  2012;
Szczepankiewicz  et  al.,  2011;  Gałecka  et  al.,  2013).  Three
studies  examined  recurrent  MDD  versus  controls  in  retro-
spect  (Van  West  et  al.,  2006;  Zobel  et  al.,  2008;  Gałecka
et  al.,  2013) and  found  that  N363s,  BclI  and  22/23  EK  were
associated  with  recurrent  MDD.  Only  one  study  (Bet  et  al.,
2009) investigated  interactions  and  found  that  an  interac-
tion  between  the  GR  polymorphisms  22/23  EK  and  9  and
childhood  trauma  resulted  in  an  increased  risk  for  devel-
oping  depressive  symptoms  at  old  age.  To  the  best  of  our
knowledge,  there  is  no  research  which  investigated  prospec-
tively  whether  these  variants  are  associated  with  recurrence
of  MDD.
We  aimed  to  investigate  retrospectively  as  well  as
prospectively  whether  the  SNPs  located  on  the  GR  and  MR
which  are  associated  with  glucocorticoid  sensitivity  and  MDD
are  also  associated  with  recurrence  of  MDD.  Furthermore,
we  investigated  whether  these  SNPs  interact  with  stressful
conditions  (childhood  trauma,  life  events).  Our  hypothesis
was  that  polymorphisms  of  the  GR  and  MR  gene  associated
with  glucocorticoid  sensitivity  and  depression  increase  the
risk  of  a  recurrent  course  of  depression  or  a  faster  time  to
recurrence.  Moreover,  we  hypothesized  that  these  polymor-
phisms  interact  with  stressful  conditions  (childhood  trauma,
recent  life  events),  increasing  the  risk  for  a  recurrence.
2.  Methods
2.1.  Study  sample
Data  were  from  the  Netherlands  Study  of  Depression  and
Anxiety  (NESDA),  a prospective  cohort  study  investigating
the  long-term  course  of  depressive  and  anxiety  disorders.
At  baseline,  2981  subjects  (18—65  years)  were  recruited
in  primary  care,  in  specialized  mental  health  care  and  in
the  community.  The  study  protocol  was  approved  by  the
Ethical  Committee  of  participating  universities.  All  sub-
jects  provided  written  informed  consent.  The  rationale,
objectives,  and  methods  of  NESDA  have  been  described
in  detail  elsewhere  (Penninx  et  al.,  2008).  In  brief,  the
NESDA  cohort  (n  =  2981)  consists  of  subjects  (18—65  years)
with  (i)  a  current  anxiety  and/or  depressive  disorder,  (ii)  a
prior  history  of  a  depressive  and/or  anxiety  disorder  and
(iii)  healthy  controls.  Subjects  were  recruited  in  primary
care  through  a  screening  procedure,  in  specialized  men-
tal  health  care  upon  registration  and  in  the  community.
All  2981  subjects  were  administered  a  baseline  assessment,
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which  lasted  on  average  4  h  and  included  assessment  of
psychopathology,  demographic  and  personal  characteristics,
psychosocial  functioning,  and  biomarkers.  Based  on  clin-
ical  judgment  and  if  necessary  screening  of  the  medical
records,  subjects  with  a  primary  diagnosis  of  psychotic
disorder,  obsessive—compulsive  disorder,  bipolar  disorder,
severe  addiction  disorder,  and  those  not  ﬂuent  in  Dutch
were  excluded.  All  subjects  were  from  Northern-European
ancestry.
For  our  present  study,  the  ﬁrst  4  years  were  used.  We
selected  subjects  with  a  lifetime  history  of  MDD  (n  =  1925).
The  diagnosis  was  assessed  at  baseline  and  based  on  the
DSM-IV  based  Composite  International  Diagnostic  Interview
(CIDI),  lifetime  version  2.1.  Of  these,  55  subjects  were
excluded  because  they  did  not  have  DNA  data  or  that  the
samples  of  these  subjects  did  not  pass  basic  quality  control
(see  GR  and  MR  variants  section).  Subjects  with  or  without
DNA  data  did  not  differ  in  age,  sex  or  history  of  recurrent
MDD.  We  applied  two  different  analytic  approaches.  First,
we  analyzed  in  retrospect  whether  subjects  with  GR  and
MR  polymorphisms  associated  with  glucocorticoid  sensitiv-
ity  more  often  had  a  recurrent  MDD  (n  =  951)  as  compared
to  those  having  a  single  episode  (n  =  919).  Second,  in  a  more
stricter  approach  we  selected  those  who  were  in  remission
of  MDD  for  at  least  6  months  preceding  the  baseline  assess-
ment  and  assessed  time  to  recurrence  prospectively  during
4  years  using  the  life  chart  interview  (LCI)  (Lyketsos  et  al.,
1994).  The  LCI  uses  age-  and  calendar-linked  personal  land-
marks  to  describe  time  sequence  of  symptoms  of  MDD.  In
this  way,  it  was  possible  to  assess  time  to  recurrence  of  MDD
per  month  follow-up.  Recurrence  was  deﬁned  as  recurrence
of  symptoms  after  remission  to  at  least  mild  severity  level
persisting  for  at  least  1  month  with  the  additional  crite-
rion  that  a  CIDI-conﬁrmed  MDD  diagnosis  was  present  during
follow-up.  810  subjects  fulﬁlled  the  deﬁnition  of  a  remitted
MDD  diagnosis.  Of  these,  18  subjects  were  excluded  because
these  subjects  did  not  collect  DNA  data  or  the  DNA  samples
did  not  pass  basic  quality  control.  80  subjects  (10.1%)  were
excluded  because  they  did  not  have  a  (complete)  LCI  during
follow-up  or  were  lost  to  follow-up.  Drop-out  was  associ-
ated  with  lower  educational  attainment  (F  =  1.99,  p  =  0.05),
but  not  with  sex  or  age.  Finally,  29  subjects  were  excluded
because  the  diagnosis  changed  to  bipolar  disorder  during
follow-up.  Consequently,  in  683  subjects  GR  and  MR  poly-
morphisms  could  be  analyzed  prospectively  for  recurrence
of  MDD.
2.2.  GR  and  MR  variants
For  the  present  study,  MR  and  GR  SNPs  were  selected  which
in  previous  research  were  associated  with  glucocorticoid
sensitivity  (Spijker  and  van  Rossum,  2012).  For  the  GR  gene
these  are:  22/23  EK  (rs6189/rs6190,  GAGAGG  >  GAAAGG),  9
(rs6198,  A  >  G),  N363S  (rs56149945,  previously  coded  rs6195,
AAT  >  AGT),  TthIIII (rs10052957,  C  >  T)  NR3C1-1  (rs10482605,
T  >  C)  and  BclI  (rs41423247,  C  >  G).  For  the  MR  gene  these
are:  −2  G/C  (rs2070951,  G  >  C)  and  I180V  (rs5522,  A  >  G).
Genotyping  of  the  SNPs  was  performed  on  two  platforms:
OpenArray® Real  time  PCR  System  (Life  Technologies,  Carls-
bad,  USA)  and  Affymetrix  6.0  (Santa  Clara,  CA;  Perfegen
5.0,  Mountain  View,  CA,  USA)  which  was  imputed  against
the  1000  genomes  (1KG  Phase  reference  panel  1  release  ver-
sion  3  2012-03-14).  Subjects  were  excluded  based  on  a  SNP
genotype  missing  rate  of  >10%,  heterozygosity  −0.1  <  F  <  0.1
or  when  the  X  chromosome  status  did  not  match  phenotype
sex.  Best  guess  genotype  data  was  used  based  on  a  cut-off
of  0.90.  Allele  frequencies  lower  than  1%  were  excluded.
For  the  data  retrieved  from  OpenArray® Real  time  PCR  Sys-
tem,  also  samples  with  a  call  rate  <95%  were  removed.  The
retrieved  SNP  data  were  highly  correlated  (Pearson  square
>0.95).  Because  the  number  of  usable  DNA  samples  was
larger  in  the  Affymetrix  6.0  dataset,  this  dataset  was  used.
An  exception  was  −2  G/C  which  could  only  be  retrieved
through  OpenArray® Real  time  PCR  System.
2.3.  Stress  related  factors
We  determined  two  types  of  stress  related  factors:  negative
life  events  in  the  last  year  and  childhood  trauma.  Number
of  negative  life  events  were  determined  with  the  Brugha
questionnaire  (Brugha  et  al.,  1985) which  included  12  spe-
ciﬁc  events  and  one  ‘other’  category  asking  about  serious
other  negative  life  events.  The  number  of  life  events  in  the
past  year  was  calculated.  For  childhood  trauma  a  cumula-
tive  childhood  index  was  constructed  (Wiersma  et  al.,  2009;
Hovens  et  al.,  2010)  by  asking  four  questions  regarding  the
occurrence  and  frequency  of  childhood  experiences  of  emo-
tional  neglect,  or  emotional,  physical,  or  sexual  abuse.  A
cumulative  index  was  calculated  as  the  sum  of  the  number
and  frequency  of  the  four  types  of  abuse  for  each  subject
in  line  with  earlier  studies  (Wiersma  et  al.,  2009;  Hovens
et  al.,  2010).
2.4.  Covariates
Besides  age  and  sex,  pharmacological  treatment  was  also
considered  a covariate  based  on  previous  studies  (Brouwer
et  al.,  2006;  Anacker  et  al.,  2011).  This  was  assessed  based
on  inspection  of  the  medication  boxes  used  in  the  past
month  and  coded  using  the  WHO  Anatomical  Therapeutic
Chemical  (ATC)  classiﬁcation  (REF  to  URL).  Regular  use  of
antidepressants  was  categorized  into  selective  serotonin
reuptake  inhibitors  (ATC-code  N06AB),  tricyclic  antidepres-
sants  (ATC-code  N06AA)  or  other  antidepressants  (ATC-code
N06AF/N06AX).  Use  of  antidepressants  was  dichotomized
into  yes  or  no.  Furthermore,  we  took  into  account  possi-
ble  genetic  variation  in  the  Dutch  population.  An  earlier
study  performed  in  NESDA  (Abdellaoui  et  al.,  2013)  iden-
tiﬁed  three  principal  components  which  showed  signiﬁcant
correlations  with  geography,  distinguishing  between:  North
and  South,  East  and  West,  and  the  middle-band  and  the  rest
of  the  Netherlands.
2.5.  Statistical  analyses
SNPs  were  tested  for  Hardy—Weinberg  equilibrium.  Hap-
lotypes  were  created  with  Phase  (http://stephenslab.
uchicago.edu/software.html)  (Stephens  et  al.,  2001).  For
each  haplotype  three  genotype  combinations  were  dis-
tinguished  carrying  0,  1,  or  2  copies  of  the  haplotype
allele.  Power  calculations  for  the  cross  sectional  (logistic
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regression)  analyses  were  performed  with  Quanto  ver-
sion  1.2.4  (http://www.mybiosoftware.com/population-
genetics/5931),  and  indicated  that  for  the  SNP  with  the
highest  minor  allele  frequency  (rs2070951)  we  could  detect
an  OR  of  1.13  with  80%  power,  this  was  OR  =  1.92  for  the
SNP  with  the  lowest  minor  allele  frequency  (rs6189)  (cal-
culation  of  gene-effect  only,  unmatched  case  control  ratio
1:1  and  assuming  a  log  additive  model  of  inheritance).  As
recommended  by  Owzar  et  al.  (2012),  for  the  prospective
(Cox  proportional  hazards  model)  analysis  the  software  pro-
gram  R  version  3.1.2  was  used.  Calculations  indicated  that
for  the  SNP  highest  minor  allele  frequency  (rs2070951)  we
could  detect  an  HR  of  1.29  with  80%  power,  this  was  HR  =  3.00
for  the  SNP  with  the  lowest  minor  allele  frequency  (rs6189)
(event  rate  =  36.6%,  landmark  time  =  24  months,  probability
that  time  to  event  is  greater  than  landmark  time  =  19.2%,
and  assuming  a  log  additive  model).  All  other  analyses  were
performed  with  SPSS  version  20.0.  Subsequently,  associa-
tions  between  GR  and  MR  polymorphisms,  its  haplotypes  and
recurrence  (recurrent  versus  single  episode,  time  to  recur-
rence)  were  analyzed  using  multinomial  logistic  regression
analyses  and  Cox  regression  analyses,  adjusted  for  age,  sex,
principal  components  and  treatment.  Finally,  we  checked
for  interactions  between  GR  and  MR  haplotypes  and  stress
related  factors.  Interaction  terms  were  calculated  by  mul-
tiplying  the  GR  and  MR  haplotypes  by  the  stress-related
factors.  So,  nine  different  haplotypes  were  analyzed  with
two  different  stress  related  factors  (18  tests),  in  retrospect
as  well  as  prospectively.  Bonferoni  correction  for  multiple
testing  was  performed  for  GR/MR  polymorphism  analyses  (16
tests,  p  <  0.003),  haplotype  analyses  (18  tests,  p  <  0.003)  and
interaction  terms  (18  tests  <0.003).
3. Results
3.1.  Characteristics
As  mentioned  previously,  we  applied  two  different  analytic
approaches  to  assess  recurrence.  The  characteristics  are
presented  in  Table  1.  Of  the  subjects  (n  =  1870)  which  were
analyzed  in  retrospect  68.4%  were  female  and  the  mean
number  of  episodes  of  MDD  was  3.4  (sd  =  3.9).  919  subjects
(49.1%)  had  a  ﬁrst  MDD  and  50.9%  had  a  recurrent  MDD  life-
time.  As  expected,  the  average  age  of  the  subjects  was
higher  in  those  with  a  recurrent  course  (41.2  versus  42.8
years,  p  <  0.01).  In  the  longitudinal  analyses  (n  =  683)  48.8%
(n  =  333)  of  the  included  subjects  had  a  lifetime  recurrent
MDD  and  36.6%  (n  =  250)  had  a  recurrence  of  MDD  during
follow-up.  The  mean  time  to  recurrence  was  11.8  months
(sd  =  12.6).  Subjects  with  a  recurrence  of  MDD  during  follow-
up  more  often  had  a  childhood  trauma  (48.3%  versus  57.3%,
p  =  0.03)  and  used  more  often  an  antidepressant  (17.3%
versus  31.6%,  p  <  0.001).  Age  and  sex  distributions  did  not
differ  among  the  GR  and  MR  genotypes  besides  SNP  −2  G/C
of  which  less  females  had  a  GG  genotype  in  comparison  with
GC  or  CC  (62.8  versus  resp.  69.0  and  70.7,  p  =  0.03).
3.2.  MR-  and  GR  genotypes  and  haplotypes
Genotype  distributions  for  all  polymorphisms  were  in
Hardy  Weinberg  equilibrium  (Pearson  square  >0.05).  The
frequencies  of  the  GR  and  MR  SNPs  are  described  in  Table  2.
Notable,  there  were  no  individuals  in  our  study  sample  carry-
ing  homozygote  SNPs  of  rs6189/6190  TT  and  rs56149945  CC.
Concordant  with  previous  studies  (Van  Winsen  et  al.,  2009;
Spijker  et  al.,  2011;  Klok  et  al.,  2011),  six  main  haplotypes
were  found  for  GR  and  three  for  MR.  Frequencies  are  dis-
played  in  Table  3. Both  haplotypes  of  GR  and  MR  (haplotypes
1)  with  the  highest  frequencies  consisted  of  the  major  alleles
of  the  measured  SNPs.  After  post  hoc  Bonferroni  correction
for  multiple  testing  (p  <  0.003),  no  associations  between  the
GR  and  MR  SNPs,  its  haplotypes  and  recurrence  of  depression
were  found  (Tables  2  and  3).  Also  no  consistent  interaction
terms  (p  <  0.003)  between  stress  related  factor  and  GR/MR
haplotypes  were  found  (Table  4).  Although  non-signiﬁcant
after  Bonferoni  correction,  there  are  results  worth  men-
tioning.  Two  copies  of  the  haplotype  characterized  by  the
minor  allele  of  −2 C/G  of  the  MR  were  associated  with
time  to  recurrence  (HR  =  0.53,  95%  CI  =  0.29—0.94,  p  =  0.03)
indicating  a  protective  effect  (Table  3).  Subjects  with  two
copies  of  the  haplotype  TCTCCAA  (BclI,  TthIIIl) of  the  GR  had
more  often  a  recurrent  course  in  comparison  with  those  with
one  or  zero  copies  (OR  =  2.75,  95%  CI  1.07—7.03,  p  =  0.04)
(Table  3).  Two  copies  of  this  haplotype  was,  on  the  other
hand,  also  associated  with  a  longer  time  to  recurrence
(33.5  months  versus  11.9  and  11.3,  p  =  0.002).  It  should
be  noted  that  in  this  later  analyses  the  number  of  sub-
jects  who  had  two  copies  of  the  haplotype  4  was  only
four.  Also  two  interactions  need  to  be  addressed,  GR  haplo-
type  CGTCCGA  (9,  NR3C1-1,  TthIIIl) with  childhood  trauma
(HR  =  0.74,  95%  CI  =  0.60—0.92,  p  = 0.01)  and  GR  haplotype
TGCCCAG  (N363S)  with  recent  life  events  (HR  =  7.75,  95%
CI,  1.07—56.10,  p  =  0.04)  because  of  the  low  p-values  (see
Table  4).  However,  considering  the  number  of  tests  con-
ducted  and  the  inconsistency  of  the  ﬁndings  with  contrasting
ﬁndings  in  the  retrospective  and  prospective  analyses,  we
consider  these  chance  ﬁndings.
Our  recent  study  (Hardeveld  et  al.,  2014)  published  in  this
journal  concluded  that  the  cortisol  awakening  response  was
associated  with  time  to  recurrence  of  MDD  and  it  was  postu-
lated  that  an  increased  cortisol  awakening  response  (CAR)
could  also  be  a  genetic  vulnerability  trait.  Therefore,  we
also  investigated  whether  the  CAR  was  associated  with  GR
and  MR  polymorphisms  in  our  study  sample.  The  methods
of  the  HPA-axis  parameters  measurements  were  described
in  our  recent  study  (Hardeveld  et  al.,  2014).  For  this  analy-
ses  we  used  the  baseline  sample  (n  =  2981).  Eventually,  1211
subjects  were  included,  after  excluding  invalid  CAR  data
or  DNA  data.  Using  ANOVA,  no  associations  between  CAR
and  the  investigated  haplotypes  were  found.  We  also  ana-
lyzed  a  possible  interaction  of  CAR  by  haplotype  on  time  to
recurrence  (n  =  490).  However,  no  interactions  were  found.
4.  Discussion
This  study  did  not  ﬁnd  consistent  associations  between  GR
and  MR  polymorphisms,  interactions  with  childhood  trauma
or  recent  life  events  and  recurrence  of  MDD.  So,  our  results
suggest  that  these  polymorphisms  may  be  associated  with
onset  and  presence  of  MDD  (Van  Rossum  et  al.,  2006;  Van
West  et  al.,  2006;  Kuningas  et  al.,  2007;  Zobel  et  al.,  2008;
Krishnamurthy  et  al.,  2008;  Bet  et  al.,  2009;  Otte  et  al.,
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Table  1  Characteristics  of  the  subjects  in  the  retrospective  and  prospective  cohort.
Life  time  MDD  (n  =  1870)  Recurrence  during  follow-up  (n  =  683)
First  (n  =  919)  Recurrent
(n  =  951)
p  No  recurrence
(n  =  433)
Recurrence
(n  =  250)
p
Socio-demographic  factors
Female,  n  (%) 616  (67.0)  664  (69.8)  0.19  300  (69.3)  190  (76.0)  0.06
Age, mean  years  (sd) 41.2  (12.9) 42.8  (11.8) <0.01 44.4  (12.8)  42.6  (12.0)  0.07
Stress related  factors
Childhood  trauma,  n  (%) 513  (55.9) 558  (59.0) 0.18 210  (48.6) 142  (57.3) 0.03
Childhood trauma,  mean
(sd)
1.12  (1.23)  1.11  (1.17)  0.87  0.85  (1.07)  1.11  (1.22)  0.003
Life events  in  past  year
present,  n  (%)
403  (43.9)  379  (39.9)  0.08  144  (33.3)  96  (38.4)  0.18
Life events  in  past  year,
mean  (sd)
0.75  (1.09)  0.64  (0.94)  0.02  0.50  (0.83)  0.54  (0.80)  0.50
Treatment
Use of  antidepressants,  n
(%)
336  (36.3)  309  (32.5)  0.08  75  (17.3)  79  (31.6)  <0.001
2009;  Klok  et  al.,  2011;  Spijker  and  van  Rossum,  2012;
Szczepankiewicz  et  al.,  2011;  Gałecka  et  al.,  2013)  but  not
with  recurrence  of  MDD.  Three  studies  examined  recurrent
MDD  versus  healthy  controls  in  retrospect  (Van  West  et  al.,
2006;  Zobel  et  al.,  2008;  Gałecka  et  al.,  2013).  So,  these
studies  found  that  the  investigated  SNPs  were  associated
with  presence  of  recurrent  MDD  but  these  studies  did  not
investigate  recurrence  of  MDD  versus  ﬁrst  onset  which  makes
a  comparison  with  our  study  difﬁcult.  It  should  be  noted  that
also  negative  results  were  found  and  none  of  the  investi-
gated  SNPs  were  consistently  conﬁrmed  in  previous  studies.
What  could  be  explanations  for  our  negative  results?
El  Hage  et  al.  (2009)  postulated  that  gene  environmental
interactions  in  depression  involves  complex  participation  of
serotonergic  genes  modulating  responses  to  stress  through
the  HPA-axis.  Also  modulating  genes  involved  in  the  HPA-
axis,  for  example  FKPB5,  may  be  associated  with  MDD  risk
(Spijker  and  van  Rossum,  2012;  Szczepankiewicz  et  al.,
2014).  El  Hage  et  al.  (2009)  hypothesized  that  subjects  with
a  low  activity  of  5-HTTLPR  have  elevated  activity  in  the
amygdala.  A  hyperactive  amygdala  enhances  HPA-axis  func-
tioning  which  could  lead  to  sustained  hypercortisolism  which
is  associated  with  recurrence  of  MDD  (Hardeveld  et  al.,
2014).  Whether  sustained  hypercortisolism  will  be  present
is  also  dependent  on  MR  and  GR  expression  which  is  modu-
lated  by  FKPB5,  among  others.  In  our  study  the  CAR  was  not
associated  with  GR  and  MR  haplotypes.  So,  it  could  be  that
in  our  sample  GR  and  MR  haplotypes  did  not,  or  only  slightly,
contribute  to  hypercortisolism  and  hereby  did  not  increase
the  risk  for  a  recurrence  of  MDD.  Alternatively,  interactions
of  GR  and  MR  haplotypes  with  serotonergic  or  modulating
genes  of  the  HPA-axis  may  increase  the  risk  for  a  recurrence.
Although  an  earlier  study  using  NESDA  data  (Holleman
et  al.,  2012)  did  not  convincingly  ﬁnd  an  association  of  HPA-
axis  parameters  and  childhood  trauma,  substantial  evidence
reviewed  by  Juruena  (2014)  indicates  that  childhood  trauma
can  induce  changes  in  the  ability  of  the  HPA-axis  to  respond
to  stress  in  adulthood  by  reducing  the  ability  of  cortisol  to
bind  to  GR  and  MR.  It  was  postulated  that  an  imbalance  in
MR  and  GR  functioning  may  be  a  risk  factor  for  depression.
This  mechanism  could  also  lead  to  an  increased  awakening
response  which  we  found  to  be  associated  with  recurrence
of  MDD  (Hardeveld  et  al.,  2014).  The  contribution  of  the  GR
and  MR  polymorphisms  in  epigenetic  modiﬁcation  may  be
minor.
To  the  best  of  our  knowledge,  this  is  the  ﬁrst  study
that  investigated  GR  and  MR  polymorphisms  and  recurrence
of  MDD  prospectively.  We  examined  multiple  GR  and  MR
gene  polymorphisms  in  a  large  sample  and  used  standard-
ized  instruments  to  determine  diagnosis  and  recurrence.
However,  there  are  a  number  of  limitations.  First,  we  did
investigate  candidate  genes  which  were  associated  with  glu-
cocorticoid  sensitivity  and  MDD  but  other  SNPs  located  on
the  GR  or  MR  gene  could  be  involved  in  recurrence.  We  did
not  perform  a  whole  gene-based  association  analysis  of  SNPs
on  the  GR  and  MR.  However,  if  we  would  have  tested  more
SNPs,  requirements  for  signiﬁcance  would  have  been  more
stringent  with  accompanying  power  issues.  On  the  other
hand,  because  we  tested  several  SNPs  Bonferonni  correc-
tion  had  to  be  performed.  If  we  would  have  tested  less  SNPs
a  signiﬁcant  result  would  have  been  found.  Also,  for  some
polymorphisms  the  sample  size  was  small  or  absent  limiting
our  power  to  detect  small  to  medium  effect  sizes,  given  that
we  had  80%  power  to  detect  an  odds  ratio  1.92  for  the  SNP
with  the  lowest  minor  allele  frequency  in  the  retrospective
analyses,  this  was  HR  =  3.00  for  the  prospective  analyses.
Another  concern  relates  to  the  retrospective  collection  of
data.  The  assessment  of  a  single  episode  MDD  in  retrospect
may  not  be  accurate.  Though,  our  prospective  data  were  not
showing  associations  either.
In  conclusion,  although  there  is  considerable  evidence
that  these  polymorphisms  are  associated  with  onset  and
presence  of  MDD  no  consistent  associations  of  the  GR  and  MR
candidate  gene  polymorphisms  with  recurrence  of  MDD  were
found.  To  draw  ﬁrmer  conclusions,  replication  is  needed
preferably  using  a  whole  gene-based  association  analysis
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Table  2  Association  of  GR  and  MR  gene  polymorphisms  with  recurrence  of  MDD.a
SNP  genotype  (%) Female  (n  =  1870) Age  (n  =  1870) First  (n  =  919,  49.1%),  versus  recurrent  (n  =  951,  50.9%)
MDD at  baseline
Time  to  recurrence  during
follow-up  (n  =  683)
%  p  Mean  p  Firstb n  (%) Recurrent
n (%)
p  ORc (95%  CI) p  HRd (95%  CI) p
Glucocorticoid  receptor  gene
ER22/23EK CC  84.1 68.6 0.54 42.1 0.56 792  (98.4) 826  (98.0) 0.54 —  —  —  —
CT 1.6 63.3 42.6 13  (1.6) 17  (2.0) 1.31  (0.63—2.71) 0.54 1.36  (0.64—2.93) 0.43
N363S TT 80.2 68.3 0.30 42.0 0.52 765  (97.2) 778  (96.6) 0.52 —  —  —  —
TC 2.5 61.2 43.2 22  (2.8) 27  (3.4) 0.83  (0.46—1.47) 0.52 0.92  (0.34—2.50) 0.88
BclI GG 39.5 68.5 0.94 42.2 0.96 360  (43.5) 401  (46.4) 0.31 —  —  —  —
CG 30.6 68.0 42.1 379  (45.8) 364  (42.1) 0.87  (0.71—1.06) 0.17 0.92  (0.70—1.20) 0.52
CC 9.8 67.2 41.9 89  (10.7) 100  (11.6) 1.02  (0.74—1.40) 0.89 1.04  (0.68—1.58) 0.86
9 TT 61.0 67.1 0.82 42.1 0.37 579  (68.0) 596  (66.9) 0.89 —  —  —  —
TC 26.5 68.7 42.3 246  (28.9) 265  (29.7) 1.04  (0.85—1.29)  0.68  1.07  (0.81—1.41)  0.62
CC 3.0 71.9 39.8 27  (3.2) 30  (3.4) 1.10  (0.64—1.87)  0.74  0.71  (0.31—1.60)  0.41
TthIIIl CC 40.7 68.5 0.96 42.6 0.39 386  (49.2)  398  (47.6) 0.70 —  —  —  —
TC 35.0 68.1 42.8 324  (41.3) 350  (41.9)  1.04  (0.84—1.27)  0.74  0.85  (0.64—1.23)  0.27
TT 8.4 67.6 41.9 74  (9.4) 88  (10.5) 1.14  (0.82—1.63) 0.40 0.92  (0.60—1.42 0.72
NRC3C1-1 AA 54.7 68.4 0.85 42.4 0.51 512  (67.3) 541  (66.5) 0.93 —  —  —  —
AG 24.2 67.7 42.4 223  (29.3) 242  (29.8) 1.03  (0.83—1.28) 0.78 1.14  (0.86—1.51) 0.37
GG 2.9 71.4 40.4 26  (3.4) 30  (3.7) 1.11  (0.65—1.91) 0.71 0.52  (0.21—1.27) 0.15
Mineralocorticoid  receptor  gene
−2 G/C CC  16.4  69.0 0.03 42.2 0.80 140  (21.3)  176  (25.7) 0.16 1.23  (0.89—1.71)  0.20  1.29  (0.80—2.06)  0.29
GC 35.4  70.7  41.7  341  (52.0)  339  (49.6)  0.97  (0.74—1.28)  0.85  1.21  (0.79—1.85)  0.37
GG 17.9  62.8  42.0  175  (26.7)  169  (24.7)  —  —  —  —
I180V CC 1.5  68.3 0.38 41.0 0.56 17  (2.0)  12  (1.3) 0.30 0.67  (0.32—1.40)  0.29  1.12  (0.28—4.46)  0.87
TC 18.9  67.1  41.5  187  (21.7)  177  (19.7)  0.89  (0.70—1.12)  0.30  1.15  (0.84—1.56)  0.39
TT 71.2  61.9  42.2  658  (76.3)  712  (79.0)  —  —  —  —
Abbreviations: SNP = single nucleotide polymorphism, OR = odds ratio, HR = hazard ratio.
a GR data was completed for ER22/23EK in 1648 (85.7%) subjects, for N363S in 1592 subjects (82.7%), for BclI  in 1693 subjects (87.9%), for 9 in 1743 subjects (90.5%), for TthIIIl in 1620
(84.4%) subjects and for NRC3C1-1 in 1574 (81.8) subjects. In 1340 subjects (69.6%) MR genotyping was completed for −2 G/C and in 1763 subjects (91.6%) for I180V.
b Pearson chi-square.
c Logistic regression, adjusted for age, sex and principal components. Reference category is the major allele.
d Associations were tested with Cox regression analyses adjusted for age, sex, principal components and treatment with antidepressants. Reference category is the major allele.
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Table  3  Associations  of  GR  and  MR  haplotypes  with  recurrence  of  MDD.
Haplotypea First  (n  =  919,  49.1%),  versus  recurrent  (n  =  951,
50.9%)  MDD  at  baselinec
Time  to  recurrence  during  follow-up
(n =  683)d
Mean  time  to  recurrence
(months)e
%  nb n  (%)  OR  (95%  CI)  p  n  (%)  HR  (95%  CI)  p  Mean  (sd)  p
Glucocorticoid  receptor  gene
1.  TGTCCAG
(wildtype)
47.2 0  478  (25.6)  —  —  184  (26.9)  —  —  14.1  (13.2) 0.17
1 1005  (53.7)  0.97  (0.78—1.21)  0.79  354  (51.8)  0.96  (0.71—1.29)  0.77  11.3  (12.6)
2 387  (20.7)  0.99  (0.76—1.30  0.95  145  (21.2)  1.13  (0.80—1.60)  0.49  10.0  (11.4)
2. TCTCCAG
(BclI)
20.2 0  1189  (63.6)  —  —  428  (62.7)  —  —  11.6  (13.3) 0.60
1 618  (33.0)  0.87  (0.72—1.06)  0.18  229  (33.5)  1.05  (0.80—1.37)  0.75  12.5  (11.6)
2 63  (3.4)  0.94  (0.57—1.57)  0.82  26  (3.8)  0.90  (0.46—1.77)  0.76  8.2  (9.1)
3. CGTCCGA  (9,
NR3C1-1,  TthIIIl)
16.7 0  1324  (70.8)  —  —  484  (70.9)  —  —  11.0  (12.2) 0.29
1 492  (26.3)  1.03  (0.83—1.27)  0.80  177  (25.9)  0.99  (0.74—1.31)  0.93  13.8  (13.7)
2 54  (2.9)  1.14  (0.66—1.97)  0.64  22  (3.2)  0.69  (0.31—1.56)  0.37  11.5  (8.8)
4. TCTCCAA
(BclI, TthIIIl)
12.8 0  1473  (78.8)  —  —  531  (77.7)  —  —  11.3  (12.0) 0.002
1 374  (20.0)  0.96  (0.76—1.21)  0.74  144  (21.1)  0.86  (0.63—1.19)  0.37  11.9  (13.4)
2 23  (1.2)  2.75  (1.07—7.03)  0.04  8  (1.2)  1.21  (0.45—3.27)  0.71  33.5  (17.9)
5. TGCCCAG
(N363S)
1.5 0  1823(97.5%)  —  —  668  (97.8)  —  —  11.9  (12.6) 0.17
1 47  (2.5%)  1.18  (0.66—2.13)  0.58  15  (2.2)  0.89  (0.33—2.39)  0.81  3.25  (2.6)
2 0  —  —  —  —  —
6. CGTTTGA  (9,
ER22/23EK,
NR3C1-1,  TthIIIl)
1.1 0  1840  (98.4)  —  —  —  —  11.9  (12.6) 0.30
1 30  (1.6)  1.23  (0.63—2.72)  0.48  668  (97.8)  1.33  (0.62—2.86)  0.46  6.9  (10.4)
2 0  —  —  15  (2.2)  —  —
Mineralocorticoid  receptor  gene
1. GA
(wildtype)
49.2 0  358  (19.1)  —  —  111  (16.3)  —  —  14.2  (14.8) 0.47
1 1196  (64.0)  1.00  (0.78—1.28)  0.91  451  (66.0)  1.27  (0.86—1.87)  0.24  11.6  (12.1)
2 316  (16.9)  1.25  (0.91—1.72)  0.18  121  (17.7)  1.30  (0.82—2.07)  0.27  10.8  (12.7)
2. CA  (−2  G/C)  38.8 0  596  (31.9)  —  —  218  (31.9)  —  —  12.1  (12.9) 0.33
1 1056  (56.5)  0.95  (0.77—1.17)  0.63  397  (58.1)  0.95  (0.73—1.24)  0.82  11.1  (12.3)
2 217  (11.6)  1.00  (0.72—1.41)  0.99  68  (10.0)  0.53  (0.29—0.94)  0.03  16.0  (13.0)
3. CG  (I180V)  12.0 0  1477  (79.0)  —  —  548  (80.2)  —  —  11.3  (12.0) 0.34
1 364  (19.5)  0.89  (0.70—1.12)  0.30  130  (19.0)  1.17  (0.86—1.59)  0.32  13.8  (14.5)
2 29  (1.6)  0.67  (0.32—1.41)  0.29  5  (0.7)  1.30  (0.32—5.30)  0.71  5.5  (6.4)
Abbreviations: OR = odds ratio, HR = hazard ratio, MDD = major depressive disorder.
a Wildtype consisted of the major alleles of the six SNPs of GR haplotype respectively two SNPs of the MR haplotype. Haplotype were further characterized by the minor allele (in
brackets) of the SNP plus the major alleles of the other SNPs.
b Estimated number of haplotype copies.
c Logistic regression, adjusted for age, sex, and principal components. Reference category is zero copies of the haplotype.
d Associations were tested with Cox regression analyses, adjusted for age, sex, principal components and treatment with antidepressants.
e Associations were tested with ANOVA.
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Table  4  Interactions  of  stress  related  factors,  haplotypes  of  the  GR  and  MR  gene  on  the  risk  for  a  recurrence  of  MDD.
Haplotypea Haplotype by childhoodtrauma
(n = 1870)b
Haplotype by childhood
trauma (n = 683)c
Haplotype by recent life
events (n = 1870)b
Haplotype by recent life
events (n = 683)c
OR (95% CI) p HR (95% CI) p OR (95% CI) p HR (95% CI) p
Glucocortocoid receptor gene
1. TGTCCAG (wildtype) 1.04 (0.93—1.17) 0.51 1.14 (0.98—1.33) 0.10 1.06 (0.93—1.21) 0.41 1.18 (0.94—1.48) 0.16
2. TCTCCAG (BclI)  0.91 (0.79—1.04) 0.16 1.07 (0.89—1.29) 0.48 0.97 (0.82—1.14) 0.68 0.86 (0.65—1.15) 0.30
3. CGTCCGA (9, NR3C1-1,
TthIIIl)
1.07 (0.92—1.24) 0.36 0.74 (0.60—0.92) 0.01 0.90 (0.76—1.07) 0.23 0.95 (0.68—1.33) 0.76
4. TCTCCAA (BclI,  TthIIIl) 1.02 (0.86—1.22) 0.80 1.02 (0.80—1.32) 0.86 1.16 (0.93—1.44) 0.19 0.82 (0.53—1.25) 0.35
5. TGCCCAG (N363S) 0.70 (0.44—1.10) 0.12 0.72 (0.27—2.00) 0.52 0.77 (0.40—1.47) 0.43 7.75 (1.07—56.10) 0.04
6. CGTTTGA (9, ER22/23EK,
NR3C1-1, TthIIIl)
0.94  (0.52—1.69) 0.83 1.36 (0.85—2.17) 0.20 0.93 (0.41—2.08) 0.86 1.00 (0.50—2.02) 0.99
Mineralocorticoid receptor gene
1. GA (wildtype) 0.94 (0.82—1.08) 0.40 1.00 (0.82—1.21) 0.98 0.96 (0.82—1.13) 0.65 0.96 (0.71—1.28) 0.76
2. CA (−2 G/C) 1.00 (0.87—1.13) 0.93 1.10 (0.92—1.32) 0.31 1.05 (0.91—1.21) 0.53 1.16 (0.89—1.50) 0.28
3. CG (I180V) 1.11 (0.93—1.32) 0.22 0.84 (0.65—1.09) 0.20 0.98 (0.82—1.20) 0.81 0.77 (0.49—1.22) 0.27
Abbreviations:  OR = odds ratio, HR = hazard ratio, MDD = major depressive disorder.
a Wildtype consisted of the major alleles of the six single nucleotide polymorphisms (SNPs) of glucocorticoid gene haplotype respectively
two SNPs of the mineralocorticoid gene haplotype. Haplotype were further characterized by the minor allele (in brackets) of the SNP
plus the major alleles of the other SNPs representing the number of haplotype copies (0, 1, or 2).
b Risk for a life time recurrent course versus ﬁrst episode. Logistic regression, adjusted for age, sex and principal components.
c Time to recurrence. Associations were tested with Cox regression analyses, adjusted for age, sex, principal components and treatment
with antidepressants.
of  SNPs  on  the  GR  and  MR  also  including  interactions  with
modulating  and  serotonergic  genes.  In  this  way,  the  com-
plex  pattern  of  interaction  between  environmental  factors
and  genetic  factors  related  to  recurrence  of  MDD  could  be
further  unraveled.
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